









Markets
/
Stocks
/
nasdaq-siga
/

SIGA Technologies Inc

SIGA

6.700USD

+0.190+2.92%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

479.80MMarket Cap

6.42P/E TTM



SIGA Technologies Inc

6.700

+0.190+2.92%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of SIGA Technologies Inc

Currency: USD Updated: 2026-02-06

Key Insights

SIGA Technologies Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 121 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SIGA Technologies Inc's Score

Industry at a Glance

Industry Ranking

121 / 159

Overall Ranking

430 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

SIGA Technologies Inc Highlights

StrengthsRisks

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.23% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 138.72M.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 72.80%.

Fairly Valued

The company’s latest PE is 6.42, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 35.62M shares, decreasing 9.03% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 680.22K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.00.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of SIGA Technologies Inc is 6.54, ranking 142 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.62M, representing a year-over-year decrease of 73.83%, while its net profit experienced a year-over-year decrease of 573.67%.

Score

Industry at a Glance

Previous score

6.54

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.51

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

SIGA Technologies Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of SIGA Technologies Inc is 5.26, ranking 150 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 6.42, which is 119.83% below the recent high of 14.11 and 1277.27% above the recent low of -75.58.

Score

Industry at a Glance

Previous score

5.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 121/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for SIGA Technologies Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of SIGA Technologies Inc is 6.71, ranking 113 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.07 and the support level at 6.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.28

Change

0.43

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Neutral

RSI(14)

51.513

Neutral

STOCH(KDJ)(9,3,3)

29.414

Sell

ATR(14)

0.238

High Vlolatility

CCI(14)

-38.794

Neutral

Williams %R

58.273

Sell

TRIX(12,20)

0.223

Sell

StochRSI(14)

38.213

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

6.768

Sell

MA10

6.763

Sell

MA20

6.695

Buy

MA50

6.445

Buy

MA100

7.207

Sell

MA200

7.080

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of SIGA Technologies Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 49.74%, representing a quarter-over-quarter increase of 0.62%. The largest institutional shareholder is The Vanguard, holding a total of 2.69M shares, representing 3.75% of shares outstanding, with 7.90% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

MacAndrews & Forbes Holdings, Inc.

24.16M

Lewis (John Latane IV)

5.27M

BlackRock Institutional Trust Company, N.A.

2.77M

-4.40%

The Vanguard Group, Inc.

Star Investors

2.62M

+5.73%

Dimensional Fund Advisors, L.P.

2.43M

+1.03%

AltraVue Capital, LLC.

2.42M

-3.34%

American Century Investment Management, Inc.

1.23M

-12.27%

Citadel Advisors LLC

1.13M

-19.31%

State Street Investment Management (US)

1.03M

-6.86%

Geode Capital Management, L.L.C.

998.22K

+0.03%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SIGA Technologies Inc is 5.23, ranking 73 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.